Clinical Trials Logo

Residual Disease clinical trials

View clinical trials related to Residual Disease.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03384914 Active, not recruiting - Clinical trials for Breast Cancer Female

Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer

Start date: February 19, 2018
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to evaluate the safety of each study vaccine and to evaluate the effect on the time to disease recurrence (assessed by disease free survival). Participants will be assigned to receive one of two study vaccines (DC1 study vaccine vs. WOKVAC). The study vaccine will be administered in two phases: a study vaccination phase and a booster phase.

NCT ID: NCT03189576 Active, not recruiting - Colorectal Cancer Clinical Trials

Measuring Molecular Residual Disease in Colorectal Cancer After Primary Surgery and Resection of Metastases

Start date: October 1, 2015
Phase: N/A
Study type: Interventional

Circulating tumour DNA (ctDNA) is a promising tool when monitoring the residual disease in colorectal cancer (CRC). Current staging procedures are insufficient to identify the patient cohort at high risk, who might benefit from additional adjuvant therapy. We will show that the assessment of ctDNA is a non-invasive approach and easily taken at different time points via simple blood draw to monitor residual disease from the colorectal cancer patients after primary surgery. Minimal residual disease could be used in the future for individualized treatment decisions after primary surgery.

NCT ID: NCT02389517 Active, not recruiting - Plasma Cell Myeloma Clinical Trials

Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant

Start date: March 2, 2015
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies how well lenalidomide alone compared to lenalidomide, ixazomib citrate, and dexamethasone work in treating patients with multiple myeloma that remains (residual) after donor stem cell transplant. Lenalidomide may help the immune system kill abnormal blood cells or cancer cells and may also prevent the growth of new blood vessels that are needed for cancer growth. Ixazomib citrate may stop the growth of cancer cells by interfering with proteins necessary for cell growth. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether lenalidomide is more effective with or without ixazomib citrate and dexamethasone in treating residual multiple myeloma.